Hepatocellular Carcinoma

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258. 

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258. 

Key clinical point: Statin use reduced risk of recurrence and improved survival in HCC patients who underwent liver transplants.

Major finding: Hepatocellular carcinoma patients on statins who underwent liver transplants were less likely to experience HCC recurrence (adjusted hazard ratio 0.3), HCC-related mortality (aHR 0.4) and all-cause mortality (aHR 0.3) compared to patients not on statins; a dose-dependent relationship occurred between statin use and HCC recurrence.

Study details: The data come from 430 consecutive HCC patients who underwent liver transplantation between 1995 and 2019; 107 were statin users and 323 were not.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Lee HL et al. Liver Transpl. 2021 Aug 9. doi: 10.1002/lt.26258. 

Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.

Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.

Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.

Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.

Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.

Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.

Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.

Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.

Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.

Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.

Key clinical point: The albumin-bilirubin (ALBI) grade and alpha-fetoprotein (AFP) level of HCC patients at the start of regorafenib therapy was an independent predictor of disease control, progression-free survival after regorafenib therapy, and overall survival for both regorafenib and sorafenib-regorafenib sequential therapy.

Major finding: HCC patients with ALBI grade 2 and AFP level of 20 ng/mL or higher had worse rates of both progression-free survival for regorafenib alone (hazard ratio 3.088) and of overall survival for both regorafenib (HR 3.783) and sorafenib-regorafenib sequential therapy (HR 4.603) compared to those with ALBI grade one and lower AFP levels.

Study details: The data come from 88 adults with unresectable hepatocellular carcinoma who were treated with sorafenib-regorafenib sequential therapy.

Disclosures: The study received no outside funding. One study coauthor disclosed serving as an advisory committee member for AbbVie, Bristol-Myers Squibb, Gilead, and Roche. The lead author and other researchers had no financial conflicts to disclose.

Source: Wang H-W et al. Cancers (Basel). 2021 Jul 26. doi: 10.3390/cancers13153758.

Key clinical point: A prognostic nomogram based on six novel factors accurately predicted outcomes in patients with unresectable HCC after HAIC.

Major finding: After a median of 35.4 months, 358 patients died; the C-index of a nomagram using C-reactive protein, albumin-bilirubin grade, alpha fetoprotein, extrahepatic metastasis, portal vein invasion, and tumor size was 0.710, significantly better than a nomogram using six conventional staging systems.

Study details: The data come from 463 adults with unresectable hepatocellular carcinoma who initially received hepatic arterial infusion chemotherapy (HAIC) between January 2016 and December 2018.

Disclosures: The study was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, Science and Technology Planning Project of Guangdong Province, Science and Technology Planning Project of Guangzhou, and Clinical Trials project 5010 of Sun Yat-sen University. The researchers had no financial conflicts to disclose.

Source: Mei J et al. Eur J Radiol. 2021 Aug 4. doi: 10.1016/j.ejrad.2021.109890.

Key clinical point: A prognostic nomogram based on six novel factors accurately predicted outcomes in patients with unresectable HCC after HAIC.

Major finding: After a median of 35.4 months, 358 patients died; the C-index of a nomagram using C-reactive protein, albumin-bilirubin grade, alpha fetoprotein, extrahepatic metastasis, portal vein invasion, and tumor size was 0.710, significantly better than a nomogram using six conventional staging systems.

Study details: The data come from 463 adults with unresectable hepatocellular carcinoma who initially received hepatic arterial infusion chemotherapy (HAIC) between January 2016 and December 2018.

Disclosures: The study was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, Science and Technology Planning Project of Guangdong Province, Science and Technology Planning Project of Guangzhou, and Clinical Trials project 5010 of Sun Yat-sen University. The researchers had no financial conflicts to disclose.

Source: Mei J et al. Eur J Radiol. 2021 Aug 4. doi: 10.1016/j.ejrad.2021.109890.

Key clinical point: A prognostic nomogram based on six novel factors accurately predicted outcomes in patients with unresectable HCC after HAIC.

Major finding: After a median of 35.4 months, 358 patients died; the C-index of a nomagram using C-reactive protein, albumin-bilirubin grade, alpha fetoprotein, extrahepatic metastasis, portal vein invasion, and tumor size was 0.710, significantly better than a nomogram using six conventional staging systems.

Study details: The data come from 463 adults with unresectable hepatocellular carcinoma who initially received hepatic arterial infusion chemotherapy (HAIC) between January 2016 and December 2018.

Disclosures: The study was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, Science and Technology Planning Project of Guangdong Province, Science and Technology Planning Project of Guangzhou, and Clinical Trials project 5010 of Sun Yat-sen University. The researchers had no financial conflicts to disclose.

Source: Mei J et al. Eur J Radiol. 2021 Aug 4. doi: 10.1016/j.ejrad.2021.109890.

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: Use of MRI in men with PSA levels suggestive of prostate cancer was noninferior to standard biopsy in detecting clinically significant prostate cancer.

Major finding: Clinically significant cancer was identified in 192 men in the experimental biopsy group and 106 men in the standard group; the percentage of clinically insignificant cancers was significantly lower in the experimental biopsy group compare to the standard group (4% vs 12%),

Study details: The data come from a population-based noninferiority trial of 1532 men aged 50 to 74 years with PSA levels of 3 ng/mL or higher. The men were randomized to standard biopsy or experimental biopsy using MRI.

Disclosures: The study was supported by the Swedish Research Council,  the Swedish Cancer Society, the Percy Falk Foundation, the Magnus Bergvall Foundation, the Strategic Research Program on Cancer at Karolinska Institutet, the Hagstrand Memorial Fund, Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, the Swedish e-Science Research Center (SeRC), Karolinska Institutet, and the Swedish Prostate Cancer Foundation. The researchers had no financial conflicts to disclose.

Source: Eklund M et al. N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852. 

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: The use of high-dose-rate brachytherapy was associated with significantly higher quality-of-life scores over the first 36 months post-treatment compared to low-dose-brachytherapy.

Major finding: No significant differences in toxicity were noted between the high-dose and low-dose groups, and quality-of-life scores were significantly higher in the high-dose patients. PSA nadir was significantly higher with HDRB compared to LDRB (1.02 vs 0.25, P < 0.0001, and significantly more LDRB patients reached a PSA of less than 0.4 ng/mL (13 vs 2, P < 0.0001).

Study details: The data come from a phase 2 randomized pilot study in which 15 men with low-risk and favorable-intermediate-risk prostate cancer underwent Low-Dose-Rate Brachytherapy (LDRB) and 16 underwent High-Dose-Rate Brachytherapy (HDRB).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Reynaud T et al. Brachytherapy. 2021 Jul 5. doi: 10.1016/j.brachy.2021.05.010.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: During a median follow-up of 13 months, the rate of progression was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide, and patients in the enzalutamide group had more favorable profiles for radiological progression-free survival and overall survival.

Major finding: The rate of metastatic prostate cancer at diagnosis was significantly higher in patients treated with abiraterone acetate compared to those treated with enzalutamide (P = 0.016); enzalutamide patients had increased radiological progression-free survival and overall survival.

Study details: The data come from a retrospective study of 250 men diagnosed with metastatic castration-resistant prostate cancer who were treated with either abiraterone acetate or enzalutamide.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Demirci A et al. Sci Rep. 2021 Jul 8. doi: 10.1038/s41598-021-93659-x.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: Signs of systemic inflammation were significantly lower among white male prostate cancer patients compared to matched controls, but no difference in these measures was observed between cases and controls among black men.

Major finding: Among black men, trajectories in neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) were similar between prostate cancer patients and controls. Among white men, both NLR and MLR values were higher among controls compared to prostate cancer patients.

Study details: The data come from 10 478 men with benign prostate cancer who were followed for up to 18 years; researchers created a nested case-control study of 822 pairs.

Disclosures: The study was supported by the National Institute of Environmental Health Sciences. The researchers had no financial conflicts to disclose.

Source: Rundle AG et al. PLoS One. 2021 Jul 9. doi: 10.1371/journal.pone.0252951.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: The risk of hematologic toxicities was significantly higher for metastatic castration-resistant prostate cancer patients treated with cabazitaxel compared to those treated with docetaxel.

Major finding: Within 8 months of treatment initiation, 61% of patients given cabazitaxel were treated for hematologic toxicity, vs 31% of docetaxel patients; median overall survival was 11.3 months with cabazitaxel vs 21.9 months with docetaxel.

Study details: The data come from a retrospective claims study of metastatic castration-resistant prostate cancer (mCRPC) patients who received either cabazitaxel (539 patients) or docetaxel (240 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Kreis K et al. BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.

Key clinical point: No significant difference was noted in high b-value 3.0 T biparametric magnetic resonance with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) compared with standard PI-RADS in biopsy-naïve men.

Major finding: The area under the curve values of these two methods for detecting prostate cancer were 0.905 and 0.892, respectively, and the AUC values for detecting clinically significant prostate cancer were 0.919 and 0.906, respectively.

Study details: The data come from a retrospective study of 224 adult men who underwent prostate cancer biopsy after imaging by two different radiologists, using the multi-parameter magnetic resonance imaging (mp-MRI) with the prostate imaging report and data system version 2 (PI-RADS v2), and biparametric magnetic resonance imaging (bp-MRI) with the simplified prostate image reporting and data system (S-PI-RADS). 

Disclosures: The study was supported by Key R & D Project of Hainan Province. The researchers had no financial conflicts to disclose.

Source: Wang G et al. Clin Imaging. 2021 Jun 29. doi: 10.1016/j.clinimag.2021.06.024.